Diabetische Nierenerkrankung (Update 2023)

[1]  Connie M. Rhee,et al.  Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) , 2022, Diabetes care.

[2]  Chava L. Ramspek,et al.  Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  N. Cook,et al.  Sodium and Health: Old Myths and a Controversy Based on Denial , 2022, Current Nutrition Reports.

[4]  R. Nelson,et al.  Structural Lesions on Kidney Biopsy in Youth-Onset and Adult-Onset Type 2 Diabetes. , 2022, Diabetes care.

[5]  Patrizia Calella,et al.  No additional benefit of prescribing a very low-protein diet in patients with advanced Chronic Kidney Disease under regular nephrology care: a pragmatic, randomized, controlled trial. , 2021, The American journal of clinical nutrition.

[6]  G. Heinze,et al.  Estimation of the prevalence of chronic kidney disease in people with diabetes by combining information from multiple routine data collections , 2021, Journal of the Royal Statistical Society: Series A (Statistics in Society).

[7]  K. Khunti,et al.  KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. , 2020, Kidney international.

[8]  C. L. le Roux,et al.  Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus , 2020, Nature Reviews Nephrology.

[9]  H. Mozaffari,et al.  Dietary Approaches to Stop Hypertension and risk of chronic kidney disease: A systematic review and meta-analysis of observational studies. , 2020, Clinical nutrition.

[10]  J. Auer,et al.  [Austrian Consensus on High Blood Pressure 2019]. , 2019, Wiener klinische Wochenschrift.

[11]  N. Powe,et al.  Poor accordance to a DASH dietary pattern is associated with higher risk of ESRD among adults with moderate chronic kidney disease and hypertension. , 2019, Kidney international.

[12]  C. Zoccali,et al.  Lipid management in patients with chronic kidney disease , 2018, Nature Reviews Nephrology.

[13]  F. Azizi,et al.  Adherence to low-sodium Dietary Approaches to Stop Hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: a secondary prevention in prospective cohort study , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  C. Cannon,et al.  Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. , 2018, Kidney international.

[15]  C. Wanner,et al.  Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes—A Proposed MARE Definition , 2018, Kidney international reports.

[16]  M. D. de Broe,et al.  Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4 , 2018, Diabetes Care.

[17]  I. D. de Boer,et al.  Diabetes and Hypertension: A Position Statement by the American Diabetes Association , 2017, Diabetes Care.

[18]  G. Heinze,et al.  Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  Bryan C. Batch,et al.  Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a pilot feeding study , 2016, Clinical kidney journal.

[20]  J. Lv,et al.  Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  S. Bangalore,et al.  Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials , 2016, British Medical Journal.

[22]  G. Mayer,et al.  Diabetes-related end-stage renal disease in Austria 1965-2013. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  S. Colagiuri,et al.  Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. , 2015, Diabetes research and clinical practice.

[24]  A. Krolewski.  Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes , 2015, Diabetes Care.

[25]  D. Bolignano,et al.  Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  J. Gerich,et al.  Hypoglycemia in Patients with Diabetes and Renal Disease , 2015, Journal of clinical medicine.

[27]  Silvio E. Inzucchi,et al.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review. , 2014, JAMA.

[28]  Mark E Molitch,et al.  Diabetic Kidney Disease: A Report From an ADA Consensus Conference , 2014, Diabetes Care.

[29]  D. Wonderling,et al.  Early identification and management of chronic kidney disease in adults: summary of updated NICE guidance , 2014, BMJ : British Medical Journal.

[30]  M. Tonelli,et al.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.

[31]  D. Nathan,et al.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview , 2013, Diabetes Care.

[32]  W. Cushman,et al.  Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease , 2013, Annals of Internal Medicine.

[33]  Mahboob Rahman,et al.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  J. Franch-Nadal,et al.  Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study , 2013, BMC Nephrology.

[35]  F. Prischl,et al.  Diabetische Nephropathie – Update 2012 , 2012, Wiener klinische Wochenschrift.

[36]  G. Schernthaner,et al.  Aktuelle Therapie des Typ-2-Diabetes , 2012, Der Internist.

[37]  M. Tonelli,et al.  Benefits and Harms of Statin Therapy for Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[38]  A. Amin,et al.  Toward more accurate detection and risk stratification of chronic kidney disease. , 2012, JAMA.

[39]  Keith C. Norris,et al.  Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). , 2012, Archives of internal medicine.

[40]  D. Gordin,et al.  The Association Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 Diabetes , 2011, Diabetes Care.

[41]  W. Herrington,et al.  Metformin: The Safest Hypoglycaemic Agent in Chronic Kidney Disease? , 2011, Nephron Clinical Practice.

[42]  Merlin C. Thomas,et al.  Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[43]  H. Pilmore.  Review: Metformin: Potential benefits and use in chronic kidney disease , 2010, Nephrology.

[44]  R. Atkins,et al.  Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  Merlin C. Thomas,et al.  Nonalbuminuric Renal Impairment in Type 2 Diabetic Patients and in the General Population (National Evaluation of the Frequency of Renal Impairment cO-existing with NIDDM [NEFRON] 11) , 2009, Diabetes Care.

[46]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[47]  J. Tayek.  SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics , 2008, Diabetes, obesity & metabolism.

[48]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[49]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[50]  Rury R Holman,et al.  Risk Factors for Renal Dysfunction in Type 2 Diabetes , 2006, Diabetes.

[51]  M. Hanefeld,et al.  A long‐term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double‐blind, parallel‐group comparison trial , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[52]  M. Hanefeld,et al.  Long‐term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study , 2005, Diabetes/metabolism research and reviews.

[53]  M. Hanefeld,et al.  Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. , 2004, The Journal of clinical endocrinology and metabolism.

[54]  Quan Dong Nguyen,et al.  Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. , 2003, JAMA.

[55]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[56]  A. Scheen.  Clinical Pharmacokinetics of Metformin , 1996, Clinical pharmacokinetics.

[57]  P. Kimmelstiel,et al.  Studies on renal biopsy specimens, with the aid of the electron microscope. I. Glomeruli in diabetes. , 1962, American journal of clinical pathology.

[58]  OUP accepted manuscript , 2021, European Heart Journal.

[59]  M. Hanefeld,et al.  One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. , 2004, Diabetes care.

[60]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.